Treatment for cannabis use disorder
大麻使用障碍的治疗
基本信息
- 批准号:10546566
- 负责人:
- 金额:$ 31.99万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-08-01 至 2024-07-31
- 项目状态:已结题
- 来源:
- 关键词:Adverse effectsAffectAgonistAmericanAnhedoniaAnimalsAnti-Obesity AgentsAreaAwardBehavioralBenignBrainCNR1 geneCNR2 geneCanis familiarisCannabinoidsCannabisCellsChemicalsClinical DataCognitive TherapyDevelopmentDoseEmergency department visitEmotionalEuropeFDA approvedFailureG-Protein-Coupled ReceptorsGenerationsGoalsHumanImmuneLeadLegal patentMarijuanaMaximum Tolerated DoseOralOrganOutcomePenetrationPeripheralPharmaceutical PreparationsPharmacotherapyPhasePhysiologicalPlasmaProductionPropertyRattusReceptor SignalingResearch DesignRewardsRodentRouteSelf StimulationSignal TransductionSmall Business Innovation Research GrantSubstance Use DisorderTetrahydrocannabinolTherapeuticToxic effectToxicokineticsToxicologyWithdrawaladdictionantagonistbasebehavioral studychemical synthesisclinical candidatecohortcravingdesigndrug discriminationdrug of abusedysphoriaexperienceimaging studyinnovationinterestlead candidatemarijuana legalizationmarijuana usemarijuana use disordernext generationnovelnovel therapeuticspreclinical studypsychologicreceptorrimonabantscale upsmall moleculesocialsynthetic cannabinoidwelfare
项目摘要
Abstract
Our goal is to develop an innovative pharmacotherapy for cannabis use disorder (CUD) that affects over 4 million
Americans. We propose to develop a novel second generation PARTIAL inverse agonist of the cannabinoid 1
receptor (CB1) that has a benign behavioral profile for CUD. Cannabinoids are the second most abused class of
drug in the world and there is no FDA approved medication for CUD -- making this an area of urgent need. The
psychoactive effects of cannabis and synthetic cannabinoids result from activation of central CB1 receptors.
Blocking the rewarding and craving properties of drugs of abuse is a well-validated and accepted strategy for
substance use disorders (SUD) without a strong adverse physical withdrawal component. Rimonabant is a potent
FULL inverse agonist of the CB1 receptor that was approved in Europe as an anti-obesity agent. Unfortunately,
rimonabant produced adverse dysphoric effects in ~6% of users -- effects likely due to sustained high brain
exposure and potent inverse agonism, which led to its eventual discontinuation. In human studies, rimonabant
was efficacious in treating many aspects of CUD. Artiam Bio is developing the next generation of CB1 antagonists
that are expected to have a superior adverse effect profile compared to rimonabant and previous clinical
candidates. Artiam Bio’s lead compound is an orally active, potent, and selective CB1 partial inverse agonist with
limited brain penetration. This compound is functionally as efficacious as rimonabant but produces no
dysphoria/anhedonia in rodent studies. Further development of this compound is proposed through three aims.
Through aim 1, ~500 g of the compound will be synthesized using an established chemical route leveraging upon
Artiam’s experience with a congener. Through aims 2 and 3, dose range finding toxicological studies will be
performed in two species and toxicokinetic parameters will be established. Successful completion of this phase 1
SBIR application will pave the way for GLP regulatory studies and other IND-enabling activities of Artiam’s lead
candidate for CUD.
摘要
我们的目标是为影响超过400万人的大麻使用障碍(CUD)开发一种创新的药物疗法
美国人我们建议开发一种新的第二代大麻素1的PARTIAL反向激动剂
受体(CB 1),具有良好的行为特征的CUD。大麻素是第二大滥用类别,
目前世界上还没有FDA批准的用于CUD的药物,这使得这一领域的需求迫切。的
大麻和合成大麻素的精神活性作用由中枢CB 1受体的激活引起。
阻断滥用药物的奖励和渴望特性是一种得到充分验证和接受的策略,
物质使用障碍(SUD),没有强烈的不良身体戒断成分。利莫那班是一种强效的
CB 1受体的完全反向激动剂,在欧洲被批准作为抗肥胖剂。不幸的是,
利莫那班在约6%的使用者中产生了不良的烦躁反应--这种反应可能是由于持续的高脑
暴露和有效的反向激动,这导致其最终停止。在人类研究中,利莫那班
在治疗慢性溃疡性结肠炎的许多方面都有效。Artiam Bio正在开发下一代CB 1拮抗剂
与利莫那班和先前的临床试验相比,
候选人Artiam Bio的先导化合物是一种口服活性,强效和选择性的CB 1部分反向激动剂,
有限的大脑渗透。该化合物在功能上与利莫那班一样有效,但不产生
啮齿动物研究中的烦躁/快感缺乏。通过三个目标提出了该化合物的进一步发展。
通过目标1,将使用建立的化学路线利用以下合成约500 g化合物:
阿蒂亚姆的经验与同类。通过目标2和3,将开展剂量范围确定毒理学研究。
在两个种属中进行,并将确定毒代动力学参数。成功完成第一阶段
SBIR申请将为GLP监管研究和Artiam领导的其他IND使能活动铺平道路
候选人CUD
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
HERBERT H SELTZMAN其他文献
HERBERT H SELTZMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('HERBERT H SELTZMAN', 18)}}的其他基金
ANANDAMIDE CONFORMERS TO PROBE THE CANNABINOID RECEPTOR
大麻素构象探索大麻素受体
- 批准号:
2458453 - 财政年份:1996
- 资助金额:
$ 31.99万 - 项目类别:
ANANDAMIDE CONFORMERS TO PROBE THE CANNABINOID RECEPTOR
大麻素构象探索大麻素受体
- 批准号:
2123524 - 财政年份:1996
- 资助金额:
$ 31.99万 - 项目类别:
ANANDAMIDE CONFORMERS TO PROBE THE CANNABINOID RECEPTOR
大麻素构象探索大麻素受体
- 批准号:
2749124 - 财政年份:1996
- 资助金额:
$ 31.99万 - 项目类别:
ANANDAMIDE CONFORMERS TO PROBE THE CANNABINOID RECEPTOR
大麻素构象探索大麻素受体
- 批准号:
2616076 - 财政年份:1996
- 资助金额:
$ 31.99万 - 项目类别:
相似海外基金
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 31.99万 - 项目类别:
Training Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 31.99万 - 项目类别:
Standard Grant
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 31.99万 - 项目类别:
Standard Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 31.99万 - 项目类别:
Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 31.99万 - 项目类别:
Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 31.99万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 31.99万 - 项目类别:
Studentship
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 31.99万 - 项目类别:
Operating Grants
New Tendencies of French Film Theory: Representation, Body, Affect
法国电影理论新动向:再现、身体、情感
- 批准号:
23K00129 - 财政年份:2023
- 资助金额:
$ 31.99万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The Protruding Void: Mystical Affect in Samuel Beckett's Prose
突出的虚空:塞缪尔·贝克特散文中的神秘影响
- 批准号:
2883985 - 财政年份:2023
- 资助金额:
$ 31.99万 - 项目类别:
Studentship